More on CGTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-16.7% Growth)
- Ratings (8.6 Score)

Upcoming Events

- Earnings (11/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Cognition Therapeutics, Inc. (NQ:CGTX)
Delayed: 1.00 +0.02 (2.04%)
Prev. Close $0.98  
Open$0.98 
52 Wk High$ 
52 Wk Low$ 
Day High$1.00 
Day Low$0.97 
P/E N/A  
EPS$ 
Volume103,338 


Aug 13, 2026 07:05 AM H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
Aug 7, 2026 07:31 AM Form 10-Q COGNITION THERAPEUTICS For: Jun 30
Aug 6, 2026 06:02 PM Cognition Therapeutics, Inc. (CGTX) Tops Q2 EPS by 1c
Aug 6, 2026 04:25 PM Form 8-K COGNITION THERAPEUTICS For: Aug 06
Aug 6, 2026 04:15 PM Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
Jul 13, 2026 07:30 AM Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
Jul 1, 2026 07:05 AM H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
Jun 24, 2026 07:39 AM Form 8-K COGNITION THERAPEUTICS For: Jun 24
Jun 24, 2026 07:30 AM FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial
Jun 24, 2026 07:30 AM Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
View All Articles

Entities mentioned with CGTX

View All Entities